- Medicine Name: Jaypirca Tablets
- Generic Name: Pirtobrutinib
- Dosage form and Strengths: Tablets: 50 mg, 100 mg
- Manufactured by: Eli Lilly and Company
Indications and Usage
Jaypirca is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Recommended Dosage: Take 200 mg orally once daily. Swallow the tablet whole with water, with or without food. Do not cut, crush, or chew the tablets.
Managing Toxicity: Toxicity can be managed through treatment interruption, dosage reduction, or discontinuation as needed.
Patients with Severe Renal Impairment: Reduce the dose in patients with severe renal impairment.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.